The nociceptin/orphanin FQ (NOP) receptor antagonist J‐113397 enhances the effects of levodopa in the MPTP‐lesioned nonhuman primate model of Parkinson's disease
Identifieur interne : 003156 ( Main/Merge ); précédent : 003155; suivant : 003157The nociceptin/orphanin FQ (NOP) receptor antagonist J‐113397 enhances the effects of levodopa in the MPTP‐lesioned nonhuman primate model of Parkinson's disease
Auteurs : Naomi P. Visanji [Canada] ; Rob M. A. De Bie [Canada, Pays-Bas] ; Tom H. Johnston [Canada] ; Andrew C. Mccreary [Pays-Bas] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada]Source :
- Movement Disorders [ 0885-3185 ] ; 2008-10-15.
English descriptors
- KwdEn :
- Analysis of Variance, Animals, Antiparkinson Agents (therapeutic use), Benzimidazoles (therapeutic use), Callithrix, Disability Evaluation, Disease Models, Animal, Drug Synergism, Levodopa (therapeutic use), MPTP, MPTP Poisoning (drug therapy), Opioid Peptides (antagonists & inhibitors), Piperidines (therapeutic use), Time Factors, dyskinesia, levodopa, marmoset, nociceptin/orphanin FQ.
- MESH :
- chemical , antagonists & inhibitors : Opioid Peptides.
- chemical , therapeutic use : Antiparkinson Agents, Benzimidazoles, Levodopa, Piperidines.
- drug therapy : MPTP Poisoning.
- Analysis of Variance, Animals, Callithrix, Disability Evaluation, Disease Models, Animal, Drug Synergism, Time Factors.
Abstract
The anti‐parkinsonian and levodopa‐sparing potential of the nociceptin/orphanin FQ receptor (NOP) antagonist J‐113397 has been demonstrated in rodent models of Parkinson's disease. Here, we describe the levodopa‐sparing potential of J‐113397 in MPTP‐lesioned marmosets. Coadministration of J‐113397 (30 mg/kg) with a sub‐therapeutic dose of levodopa (12.5 mg/kg) produced an anti‐parkinsonian action equivalent to that of a therapeutic dose of levodopa. However, these effects were accompanied by an equivalent level of dyskinesia. The actions of NOP antagonists seen in rodents translate to nonhuman primates. However, the present study raises the possibility that these levodopa‐sparing benefits may be offset by a propensity to exacerbate dyskinesia. © 2008 Movement Disorder Society
Url:
DOI: 10.1002/mds.22086
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001416
- to stream Istex, to step Curation: 001416
- to stream Istex, to step Checkpoint: 001134
- to stream PubMed, to step Corpus: 002071
- to stream PubMed, to step Curation: 002071
- to stream PubMed, to step Checkpoint: 002034
- to stream Ncbi, to step Merge: 002292
- to stream Ncbi, to step Curation: 002292
- to stream Ncbi, to step Checkpoint: 002292
Links to Exploration step
ISTEX:94F291E4B0C8056170DA9F7765D5C13E4056C439Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The nociceptin/orphanin FQ (NOP) receptor antagonist J‐113397 enhances the effects of levodopa in the MPTP‐lesioned nonhuman primate model of Parkinson's disease</title><author><name sortKey="Visanji, Naomi P" sort="Visanji, Naomi P" uniqKey="Visanji N" first="Naomi P." last="Visanji">Naomi P. Visanji</name></author><author><name sortKey="De Bie, Rob M A" sort="De Bie, Rob M A" uniqKey="De Bie R" first="Rob M. A." last="De Bie">Rob M. A. De Bie</name></author><author><name sortKey="Johnston, Tom H" sort="Johnston, Tom H" uniqKey="Johnston T" first="Tom H." last="Johnston">Tom H. Johnston</name></author><author><name sortKey="Mccreary, Andrew C" sort="Mccreary, Andrew C" uniqKey="Mccreary A" first="Andrew C." last="Mccreary">Andrew C. Mccreary</name></author><author><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name></author><author><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:94F291E4B0C8056170DA9F7765D5C13E4056C439</idno><date when="2008" year="2008">2008</date><idno type="doi">10.1002/mds.22086</idno><idno type="url">https://api.istex.fr/document/94F291E4B0C8056170DA9F7765D5C13E4056C439/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001416</idno><idno type="wicri:Area/Istex/Curation">001416</idno><idno type="wicri:Area/Istex/Checkpoint">001134</idno><idno type="wicri:doubleKey">0885-3185:2008:Visanji N:the:nociceptin:orphanin</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:18759357</idno><idno type="wicri:Area/PubMed/Corpus">002071</idno><idno type="wicri:Area/PubMed/Curation">002071</idno><idno type="wicri:Area/PubMed/Checkpoint">002034</idno><idno type="wicri:Area/Ncbi/Merge">002292</idno><idno type="wicri:Area/Ncbi/Curation">002292</idno><idno type="wicri:Area/Ncbi/Checkpoint">002292</idno><idno type="wicri:Area/Main/Merge">003156</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">The nociceptin/orphanin FQ (NOP) receptor antagonist J‐113397 enhances the effects of levodopa in the MPTP‐lesioned nonhuman primate model of Parkinson's disease</title><author><name sortKey="Visanji, Naomi P" sort="Visanji, Naomi P" uniqKey="Visanji N" first="Naomi P." last="Visanji">Naomi P. Visanji</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Toronto Western Research Institute, Toronto</wicri:regionArea><wicri:noRegion>Toronto</wicri:noRegion></affiliation></author><author><name sortKey="De Bie, Rob M A" sort="De Bie, Rob M A" uniqKey="De Bie R" first="Rob M. A." last="De Bie">Rob M. A. De Bie</name><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Neurology, University of Toronto, Toronto, Ontario</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation><affiliation wicri:level="3"><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Current Address: Department of Neurology, Academic Medical Center, Amsterdam</wicri:regionArea><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName></affiliation></author><author><name sortKey="Johnston, Tom H" sort="Johnston, Tom H" uniqKey="Johnston T" first="Tom H." last="Johnston">Tom H. Johnston</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Toronto Western Research Institute, Toronto</wicri:regionArea><wicri:noRegion>Toronto</wicri:noRegion></affiliation></author><author><name sortKey="Mccreary, Andrew C" sort="Mccreary, Andrew C" uniqKey="Mccreary A" first="Andrew C." last="Mccreary">Andrew C. Mccreary</name><affiliation wicri:level="1"><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Solvay Pharmaceuticals Research Laboratories, Weesp</wicri:regionArea><wicri:noRegion>Weesp</wicri:noRegion></affiliation></author><author><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Toronto Western Research Institute, Toronto</wicri:regionArea><wicri:noRegion>Toronto</wicri:noRegion></affiliation></author><author><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Toronto Western Research Institute, Toronto</wicri:regionArea><wicri:noRegion>Toronto</wicri:noRegion></affiliation><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Neurology, University of Toronto, Toronto, Ontario</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2008-10-15">2008-10-15</date><biblScope unit="vol">23</biblScope><biblScope unit="issue">13</biblScope><biblScope unit="page" from="1922">1922</biblScope><biblScope unit="page" to="1925">1925</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">94F291E4B0C8056170DA9F7765D5C13E4056C439</idno><idno type="DOI">10.1002/mds.22086</idno><idno type="ArticleID">MDS22086</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Analysis of Variance</term><term>Animals</term><term>Antiparkinson Agents (therapeutic use)</term><term>Benzimidazoles (therapeutic use)</term><term>Callithrix</term><term>Disability Evaluation</term><term>Disease Models, Animal</term><term>Drug Synergism</term><term>Levodopa (therapeutic use)</term><term>MPTP</term><term>MPTP Poisoning (drug therapy)</term><term>Opioid Peptides (antagonists & inhibitors)</term><term>Piperidines (therapeutic use)</term><term>Time Factors</term><term>dyskinesia</term><term>levodopa</term><term>marmoset</term><term>nociceptin/orphanin FQ</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Opioid Peptides</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Benzimidazoles</term><term>Levodopa</term><term>Piperidines</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>MPTP Poisoning</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Analysis of Variance</term><term>Animals</term><term>Callithrix</term><term>Disability Evaluation</term><term>Disease Models, Animal</term><term>Drug Synergism</term><term>Time Factors</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The anti‐parkinsonian and levodopa‐sparing potential of the nociceptin/orphanin FQ receptor (NOP) antagonist J‐113397 has been demonstrated in rodent models of Parkinson's disease. Here, we describe the levodopa‐sparing potential of J‐113397 in MPTP‐lesioned marmosets. Coadministration of J‐113397 (30 mg/kg) with a sub‐therapeutic dose of levodopa (12.5 mg/kg) produced an anti‐parkinsonian action equivalent to that of a therapeutic dose of levodopa. However, these effects were accompanied by an equivalent level of dyskinesia. The actions of NOP antagonists seen in rodents translate to nonhuman primates. However, the present study raises the possibility that these levodopa‐sparing benefits may be offset by a propensity to exacerbate dyskinesia. © 2008 Movement Disorder Society</div></front></TEI><double doi="10.1002/mds.22086"><ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The nociceptin/orphanin FQ (NOP) receptor antagonist J‐113397 enhances the effects of levodopa in the MPTP‐lesioned nonhuman primate model of Parkinson's disease</title><author><name sortKey="Visanji, Naomi P" sort="Visanji, Naomi P" uniqKey="Visanji N" first="Naomi P." last="Visanji">Naomi P. Visanji</name></author><author><name sortKey="De Bie, Rob M A" sort="De Bie, Rob M A" uniqKey="De Bie R" first="Rob M. A." last="De Bie">Rob M. A. De Bie</name></author><author><name sortKey="Johnston, Tom H" sort="Johnston, Tom H" uniqKey="Johnston T" first="Tom H." last="Johnston">Tom H. Johnston</name></author><author><name sortKey="Mccreary, Andrew C" sort="Mccreary, Andrew C" uniqKey="Mccreary A" first="Andrew C." last="Mccreary">Andrew C. Mccreary</name></author><author><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name></author><author><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:94F291E4B0C8056170DA9F7765D5C13E4056C439</idno><date when="2008" year="2008">2008</date><idno type="doi">10.1002/mds.22086</idno><idno type="url">https://api.istex.fr/document/94F291E4B0C8056170DA9F7765D5C13E4056C439/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001416</idno><idno type="wicri:Area/Istex/Curation">001416</idno><idno type="wicri:Area/Istex/Checkpoint">001134</idno><idno type="wicri:doubleKey">0885-3185:2008:Visanji N:the:nociceptin:orphanin</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">The nociceptin/orphanin FQ (NOP) receptor antagonist J‐113397 enhances the effects of levodopa in the MPTP‐lesioned nonhuman primate model of Parkinson's disease</title><author><name sortKey="Visanji, Naomi P" sort="Visanji, Naomi P" uniqKey="Visanji N" first="Naomi P." last="Visanji">Naomi P. Visanji</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Toronto Western Research Institute, Toronto</wicri:regionArea><wicri:noRegion>Toronto</wicri:noRegion></affiliation></author><author><name sortKey="De Bie, Rob M A" sort="De Bie, Rob M A" uniqKey="De Bie R" first="Rob M. A." last="De Bie">Rob M. A. De Bie</name><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Neurology, University of Toronto, Toronto, Ontario</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation><affiliation wicri:level="3"><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Current Address: Department of Neurology, Academic Medical Center, Amsterdam</wicri:regionArea><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName></affiliation></author><author><name sortKey="Johnston, Tom H" sort="Johnston, Tom H" uniqKey="Johnston T" first="Tom H." last="Johnston">Tom H. Johnston</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Toronto Western Research Institute, Toronto</wicri:regionArea><wicri:noRegion>Toronto</wicri:noRegion></affiliation></author><author><name sortKey="Mccreary, Andrew C" sort="Mccreary, Andrew C" uniqKey="Mccreary A" first="Andrew C." last="Mccreary">Andrew C. Mccreary</name><affiliation wicri:level="1"><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Solvay Pharmaceuticals Research Laboratories, Weesp</wicri:regionArea><wicri:noRegion>Weesp</wicri:noRegion></affiliation></author><author><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Toronto Western Research Institute, Toronto</wicri:regionArea><wicri:noRegion>Toronto</wicri:noRegion></affiliation></author><author><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H." last="Fox">Susan H. Fox</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Toronto Western Research Institute, Toronto</wicri:regionArea><wicri:noRegion>Toronto</wicri:noRegion></affiliation><affiliation wicri:level="4"><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Neurology, University of Toronto, Toronto, Ontario</wicri:regionArea><orgName type="university">Université de Toronto</orgName><placeName><settlement type="city">Toronto</settlement><region type="state">Ontario</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2008-10-15">2008-10-15</date><biblScope unit="vol">23</biblScope><biblScope unit="issue">13</biblScope><biblScope unit="page" from="1922">1922</biblScope><biblScope unit="page" to="1925">1925</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">94F291E4B0C8056170DA9F7765D5C13E4056C439</idno><idno type="DOI">10.1002/mds.22086</idno><idno type="ArticleID">MDS22086</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>MPTP</term><term>dyskinesia</term><term>levodopa</term><term>marmoset</term><term>nociceptin/orphanin FQ</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The anti‐parkinsonian and levodopa‐sparing potential of the nociceptin/orphanin FQ receptor (NOP) antagonist J‐113397 has been demonstrated in rodent models of Parkinson's disease. Here, we describe the levodopa‐sparing potential of J‐113397 in MPTP‐lesioned marmosets. Coadministration of J‐113397 (30 mg/kg) with a sub‐therapeutic dose of levodopa (12.5 mg/kg) produced an anti‐parkinsonian action equivalent to that of a therapeutic dose of levodopa. However, these effects were accompanied by an equivalent level of dyskinesia. The actions of NOP antagonists seen in rodents translate to nonhuman primates. However, the present study raises the possibility that these levodopa‐sparing benefits may be offset by a propensity to exacerbate dyskinesia. © 2008 Movement Disorder Society</div></front></TEI></ISTEX><PubMed><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The nociceptin/orphanin FQ (NOP) receptor antagonist J-113397 enhances the effects of levodopa in the MPTP-lesioned nonhuman primate model of Parkinson's disease.</title><author><name sortKey="Visanji, Naomi P" sort="Visanji, Naomi P" uniqKey="Visanji N" first="Naomi P" last="Visanji">Naomi P. Visanji</name><affiliation wicri:level="1"><nlm:affiliation>Toronto Western Research Institute, Toronto, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Toronto Western Research Institute, Toronto</wicri:regionArea><wicri:noRegion>Toronto</wicri:noRegion></affiliation></author><author><name sortKey="De Bie, Rob M A" sort="De Bie, Rob M A" uniqKey="De Bie R" first="Rob M A" last="De Bie">Rob M A. De Bie</name></author><author><name sortKey="Johnston, Tom H" sort="Johnston, Tom H" uniqKey="Johnston T" first="Tom H" last="Johnston">Tom H. Johnston</name></author><author><name sortKey="Mccreary, Andrew C" sort="Mccreary, Andrew C" uniqKey="Mccreary A" first="Andrew C" last="Mccreary">Andrew C. Mccreary</name></author><author><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M" last="Brotchie">Jonathan M. Brotchie</name></author><author><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H" last="Fox">Susan H. Fox</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2008">2008</date><idno type="doi">10.1002/mds.22086</idno><idno type="RBID">pubmed:18759357</idno><idno type="pmid">18759357</idno><idno type="wicri:Area/PubMed/Corpus">002071</idno><idno type="wicri:Area/PubMed/Curation">002071</idno><idno type="wicri:Area/PubMed/Checkpoint">002034</idno><idno type="wicri:Area/Ncbi/Merge">002292</idno><idno type="wicri:Area/Ncbi/Curation">002292</idno><idno type="wicri:Area/Ncbi/Checkpoint">002292</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The nociceptin/orphanin FQ (NOP) receptor antagonist J-113397 enhances the effects of levodopa in the MPTP-lesioned nonhuman primate model of Parkinson's disease.</title><author><name sortKey="Visanji, Naomi P" sort="Visanji, Naomi P" uniqKey="Visanji N" first="Naomi P" last="Visanji">Naomi P. Visanji</name><affiliation wicri:level="1"><nlm:affiliation>Toronto Western Research Institute, Toronto, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Toronto Western Research Institute, Toronto</wicri:regionArea><wicri:noRegion>Toronto</wicri:noRegion></affiliation></author><author><name sortKey="De Bie, Rob M A" sort="De Bie, Rob M A" uniqKey="De Bie R" first="Rob M A" last="De Bie">Rob M A. De Bie</name></author><author><name sortKey="Johnston, Tom H" sort="Johnston, Tom H" uniqKey="Johnston T" first="Tom H" last="Johnston">Tom H. Johnston</name></author><author><name sortKey="Mccreary, Andrew C" sort="Mccreary, Andrew C" uniqKey="Mccreary A" first="Andrew C" last="Mccreary">Andrew C. Mccreary</name></author><author><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M" last="Brotchie">Jonathan M. Brotchie</name></author><author><name sortKey="Fox, Susan H" sort="Fox, Susan H" uniqKey="Fox S" first="Susan H" last="Fox">Susan H. Fox</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2008" type="published">2008</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Analysis of Variance</term><term>Animals</term><term>Antiparkinson Agents (therapeutic use)</term><term>Benzimidazoles (therapeutic use)</term><term>Callithrix</term><term>Disability Evaluation</term><term>Disease Models, Animal</term><term>Drug Synergism</term><term>Levodopa (therapeutic use)</term><term>MPTP Poisoning (drug therapy)</term><term>Opioid Peptides (antagonists & inhibitors)</term><term>Piperidines (therapeutic use)</term><term>Time Factors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Opioid Peptides</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Benzimidazoles</term><term>Levodopa</term><term>Piperidines</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>MPTP Poisoning</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Analysis of Variance</term><term>Animals</term><term>Callithrix</term><term>Disability Evaluation</term><term>Disease Models, Animal</term><term>Drug Synergism</term><term>Time Factors</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The anti-parkinsonian and levodopa-sparing potential of the nociceptin/orphanin FQ receptor (NOP) antagonist J-113397 has been demonstrated in rodent models of Parkinson's disease. Here, we describe the levodopa-sparing potential of J-113397 in MPTP-lesioned marmosets. Coadministration of J-113397 (30 mg/kg) with a sub-therapeutic dose of levodopa (12.5 mg/kg) produced an anti-parkinsonian action equivalent to that of a therapeutic dose of levodopa. However, these effects were accompanied by an equivalent level of dyskinesia. The actions of NOP antagonists seen in rodents translate to nonhuman primates. However, the present study raises the possibility that these levodopa-sparing benefits may be offset by a propensity to exacerbate dyskinesia.</div></front></TEI></PubMed></double></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003156 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 003156 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Merge
|type= RBID
|clé= ISTEX:94F291E4B0C8056170DA9F7765D5C13E4056C439
|texte= The nociceptin/orphanin FQ (NOP) receptor antagonist J‐113397 enhances the effects of levodopa in the MPTP‐lesioned nonhuman primate model of Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |